pharmaphorum September 30, 2024
Chiesi Group has today officially launched its new Biotech Center of Excellence, with the aim that it “brings the future of medicine to Parma.”
The family-owned, global pharma company made a strategic investment of just under €400 million for establishing the Center. The state-of-the-art facility is dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins, and is designed to integrate the entire supply chain, enhancing innovation and production, and accelerating product development and autonomous production capacity.
Chiesi’s strategy aligns with EU priorities on innovation, security, and private R&D investment: the decision to establish a centre of excellence to produce biologic drugs in Italy is significant in the context of Mario Draghi’s report on European competitiveness. The report underscores...
Today's Sponsors
Today's Sponsor